We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
MIR29B regulates expression of MLLT11 (AF1Q), an MLL fusion partner, and low MIR29B expression associates with adverse cytogenetics and poor overall survival in AML.
- Authors
Yin Xiong; Zejuan Li; Min Ji; Aik-Choon Tan; Bemis, Judson; Jove-Victor Tse; Gang Huang; Jino Park; Chunyan Ji; Jianjun Chen; Bemis, Lynne T.; Bunting, Kevin D.; Tse, William
- Abstract
MLLT11, an MLL fusion partner, is a poor prognostic biomarker for paediatric acute myeloid leukaemia (AML), adult normal cytogenetics AML, and adult myelodysplastic syndrome. MLLT11 is highly regulated during haematopoietic progenitor differentiation and development but its regulatory mechanisms have not been defined. In this study, we demonstrate by transfection experiments that MIR29B directly regulates MLLT11 expression in vitro. MIR29B expression level was also inversely related to MLLT11 expression in a cohort of 56 AML patients ( P < 0·05). AML patients with low MIR29B/elevated MLLT11 expression had poor overall survival ( P = 0·038). Therefore, MIR29B may be a potential prognostic biomarker for AML patients.
- Subjects
CYTOGENETICS; LEUKEMIA; GENE expression; CHROMOSOMES; RNA; DNA
- Publication
British Journal of Haematology, 2011, Vol 153, Issue 6, p753
- ISSN
0007-1048
- Publication type
Article
- DOI
10.1111/j.1365-2141.2011.08662.x